YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company report on computer screen ©Adobe Stock Images Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.24% in pre…
(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisi…
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sci…
The chronic spontaneous urticaria market is witnessing significant growth, driven by increasing disease awareness, improved diagnosis rates, and the rising prevalence of treatment-refractory patients. The introduction of emerging therapies…
AstraZeneca AZN announced that the FDA will extend the Prescription Drug User Fee Act (PDUFA) date for reviewing the new drug application (NDA) seeking approval of camizestrant in combination with a CDK4/6 inhibitor for the first-line trea…
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the EU approval of their blo…
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), for expanded use in breast cancer. The regulatory body has n…
Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining an Outperform rating on the shares. The…
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outper…
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that compet…
Quick Read Stocks closed lower on Friday for the fourth consecutive week. Soaring oil prices and higher yields on Treasury bonds helped boost selling pressure. With inflation back in the picture and the dollar strengthening, hopes for a ra…
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete re…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 115,188,310 0.0734 0.05 0.0528 -0.0252 Beyo…
(RTTNews) - Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, on Tuesday reported encouraging preliminary data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adults with allergic asthma. A single sub…
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further developm…
(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company, is set to host a webinar to present findings from its BEACON study in chronic spontaneous urticaria, along with preliminary data from the ETESIAN study in…
(RTTNews) - Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements. Jasper Therapeutics, Inc. (JSPR) surged 21.51% to…
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Ki…
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. (NASDAQ: DRVN) and Jasper Therapeuti…
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities…
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Jasper Therapeutics, Inc. (…
LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for…
NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusi…
BENSALEM, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jas…
LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities…
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusi…
LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for…
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusi…
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Jasper Therapeutics, Inc. (…
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or other…
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jas…
ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or mis…
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for…